Financial News

J&J 4Q Results

Innovative Medicine sales were $15.8 billion in the quarter, up 10%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

4Q Revenues: $24.6 billion +9% 4Q Earnings: $5.1 billion +49% FY Revenues: $94.2 billion +6% FY Earnings: $26.8 billion +91% Comments: Innovative Medicine sales were $15.8 billion in the quarter, up 10%, primarily driven by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience.  DARZALEX sales were up 27% to $3.9 billion. CARVYKTI sales were up 66% to $555 million. ERLEADA sales were up 22...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters